Fractalkine in rheumatoid arthritis: a review to date.
Rheumatoid arthritis (RA) is characterized by the expansion of the synovium, with infiltration of pro-inflammatory cells, neovascularization and an abundance of pro-inflammatory cytokines resulting in tissue destruction and bone erosion. Fractalkine (FKN), a recently described chemokine, possesses chemotactic, angiogenic and adhesive functions that associates it with all of these destructive processes. In this review, we describe the research to date, which implicates FKN and its receptor in the pathogenesis of RA and propose that this molecule may represent a future therapeutic target for RA.
Murphy
G
G
Department of Rheumatology, Cork University Hospital, Wilton, Cork, Ireland. grainne.murphy@ucc.ie
Caplice
N
N
Molloy
M
M
D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000503:physiopathology*; D054428:Chemokine CX3CL1 / Q000037:antagonists & inhibitors / Q000502:physiology*; D002634:Chemotaxis, Leukocyte; D006801:Humans; D009389:Neovascularization, Pathologic / Q000503:physiopathology; D013583:Synovial Membrane / Q000098:blood supply / Q000473:pathology
D018501:Antirheumatic Agents; D054428:Chemokine CX3CL1